FrancophonIA/ELRC3.0 huggingface dataset:
English: The full EPAR for Pioglitazone Krka can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Pioglitazone Krka kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Pioglitazone Krka on 21 March 2012.
Estonian: Euroopa Komisjon andis Pioglitazone Krka müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 21. märtsil 2012.
English: As a consequence, the blood glucose levels are reduced and this helps to control type 2 diabetes.
Estonian: Selle tulemusel väheneb vere glükoosisisaldus, aidates sel viisil reguleerida II tüüpi diabeeti.
English: The recommended starting dose of Pioglitazone Krka is 15 or 30 mg once a day.
Estonian: Pioglitazone Krka soovitatav algannus on 15 või 30 mg üks kord ööpäevas.
English: Treatment with Pioglitazone Krka should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit.
Estonian: Pioglitazone Krka ravivastus tuleb kolme kuni kuue kuu möödudes läbi vaadata ning lõpetada ravi patsientidel, kes ei saa ravist piisavalt kasu.
English: This dose may need to be increased after one or two weeks to up to 45 mg once a day if better blood glucose (sugar) control is needed.
Estonian: Ühe või kahe nädala pärast võib annust suurendada annuseni 45 mg ööpäevas, kui on vaja vere glükoosisisaldust paremini reguleerida.
English: At subsequent reviews prescribers should confirm that benefits to patients are maintained.
Estonian: Järgmistel läbivaatamistel peab ravi määranud arst saama kinnitust, et ravist saadud kasu püsib.
English: The active substance in Pioglitazone Krka, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.
Estonian: Pioglitazone Krka toimeaine pioglitasoon suurendab rakkude (rasva-, lihas- ja maksarakud) tundlikkust insuliini suhtes, mis tähendab, et organism kasutab enda toodetavat insuliini paremini ära.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pioglitazone Krka.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: For more information about treatment with Pioglitazone Krka, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Pioglitazone Krkaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Pioglitazone Krka is a ‘generic medicine'.
Estonian: Pioglitazone Krka on geneeriline ravim.
English: Because Pioglitazone Krka is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Pioglitazone Krka on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: The Committee recommended that Pioglitazone Krka be given marketing authorisation.
Estonian: Komitee soovitas anda Pioglitazone Krka müügiloa.
English: Other information about Pioglitazone Krka
Estonian: Muu teave Pioglitazone Krka kohta
English: Because Pioglitazone Krka is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Actos.
Estonian: Et Pioglitazone Krka on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati ravimi bioekvivalentsust võrdlusravimiga Actos.
English: Pioglitazone Krka is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight.
Estonian: Pioglitazone Krkat kasutatakse eelkõige ülekaaluliste täiskasvanud (vähemalt 18-aastaste) patsientide II tüüpi diabeedi (suhkurtõve) raviks.
English: Pioglitazone Krka can also be used together with insulin in patients who are not satisfactorily controlled with insulin alone and cannot take metformin.
Estonian: Pioglitazone Krkat tohib kasutada ka koos insuliiniga patsientidel, kellele üksnes insuliini manustamine ei mõju rahuldavalt ja kes ei saa kasutada metformiini.
English: This means that Pioglitazone Krka is similar to a ‘reference medicine' already authorised in the European Union (EU) called Actos.
Estonian: See tähendab, et Pioglitazone Krka on sarnane võrdlusravimiga Actos, millel juba on Euroopa Liidus müügiluba.
English: Therefore, the CHMP's view was that, as for Actos, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Actose korral, ületab Pioglitazone Krka kasulikkus sellega kaasnevad riskid.
English: This is a summary of the European public assessment report (EPAR) for Pioglitazone Krka.
Estonian: Käesolev dokument on ravimi Pioglitazone Krka Euroopa avaliku hindamisaruande kokkuvõte.
English: Why has Pioglitazone Krka been approved?
Estonian: Miks Pioglitazone Krka heaks kiideti?
English: The CHMP concluded that, in accordance with EU requirements, Pioglitazone Krka has been shown to have comparable quality and to be bioequivalent to Actos.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Pioglitazone Krka võrdväärne kvaliteet ja bioekvivalentsus ravimiga Actos.
English: Pioglitazone Krka is a medicine that contains the active substance pioglitazone.
Estonian: Pioglitazone Krka on ravim, mis sisaldab toimeainena pioglitasooni.
English: Pioglitazone Krka should not be used in patients on dialysis (a blood clearance technique used in people with kidney disease).
Estonian: Pioglitazone Krkat ei tohi kasutada patsiendid, kes saavad dialüüsi (teatud verepuhastustehnika neeruhaiguste korral).
English: Pioglitazone Krka can also be used with a sulphonylurea (another type of antidiabetes medicine) when metformin is not suitable (‘dual therapy').
Estonian: Pioglitazone Krkat tohib kasutada ka koos sulfonüüluurearavimiga (samuti diabeediravim), kui metformiini ei saa kasutada (ravi kahe preparaadiga).
English: What are the benefits and risks of Pioglitazone Krka?
Estonian: Milles seisneb Pioglitazone Krka kasulikkus ja mis riskid Pioglitazone Krkaga kaasnevad?
English: What is Pioglitazone Krka?
Estonian: Mis on Pioglitazone Krka?
English: How has Pioglitazone Krka been studied?
Estonian: Kuidas Pioglitazone Krkat uuriti?
English: Pioglitazone Krka is used on its own in patients for whom metformin (another antidiabetes medicine) is not suitable.
Estonian: Pioglitazone Krkat kasutatakse ainsa ravimina patsientidel, kellele ei sobi metformiin (samuti diabeediravim).
English: The medicine can only be obtained with a prescription.
Estonian: Pioglitazone Krka on retseptiravim.
English: How does Pioglitazone Krka work?
Estonian: Kuidas Pioglitazone Krka toimib?
English: How is Pioglitazone Krka used?
Estonian: Kuidas Pioglitazone Krkat kasutatakse?
English: In the MRP United Kingdom is the Reference Member State (RMS) and Austria, Belgium, Finland, France, Germany, Italy, Ireland, Luxembourg, Portugal, Spain and Sweden are Concerned Member States (CMS).
Estonian: Vastastikuse tunnustamise menetluses on viiteliikmesriigiks Ühendkuningriik ning asjaomasteks liikmesriikideks Austria, Belgia, Soome, Prantsusmaa, Saksamaa, Itaalia, Iirimaa, Luksemburg, Portugal, Hispaania ja Rootsi.
English: VIANI EVOHALER and associated names (See Annex I)
Estonian: VIANI EVOHALER ja sarnaseid nimetusi (vt I lisa)
English: 4 July 2006 EMEA/306455/2006
Estonian: 4. juuli 2006 EMEA/306455/2006
English: In several EU Member States Viani Evohaler and associated names are approved through the Mutual Recognition Procedure (MRP).
Estonian: Mitmes ELi liikmesriigis on Viani Evohaler ja sarnased nimetused vastastikuse tunnustamise menetluse abil heaks kiidetud.
English: Viani Evohaler and associated names (see Annex I) contain salmeterol and fluticasone propionate, a fixed dose combination of the long acting β-agonist salmeterol and the inhaled corticosteroid fluticasone propionate and is indicated for the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: - patients not adequately controlled with inhaled corticosteroids and ‘as needed' inhaled short acting beta-2-agonist or - patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist.
Estonian: Viani Evohaler ja sarnased nimetused (vt I lisa) sisaldavad salmeterooli ja flutikasoonpropionaatipika toimeajaga beetaagonisti salmeterooli ja sissehingatava kortikosteroidi flutikasoonpropionaadi fikseeritud dooside kombinatsiooni, mis on näidustatud astma tavaraviks, kui liittoote (pika toimeajaga beeta2-agonist ja sissehingatav kortikosteroid) kasutamine on asjakohane: patsientidel, kes ei allu hästi ravile sissehingatavate kortikosteroididega ja lühikese toimeajaga vajadusel sissehingatava beeta2agonistiga, või patsientidel, kes alluvad juba tõestatult hästi ravile sissehingatava kortikosteroidi ja pika toimeajaga beeta2-agonistiga manustatuna koos.
English: The full EPAR for Palonosetron Hospira can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Palonosetron Hospira kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It is available as a solution for injection which should be given by a healthcare professional about 30 minutes before the start of chemotherapy.
Estonian: Seda turustatakse süstelahusena, mida peab manustama tervishoiutöötaja ligikaudu 30 minutit enne keemiaravi algust.
English: In adults, the recommended dose is 250 micrograms, injected into a vein over 30 seconds.
Estonian: Täiskasvanute soovituslik annus on 250 µg, mis süstitakse veeni 30 sekundi jooksul.
English: What measures are being taken to ensure the safe and effective use of Palonosetron Hospira?
Estonian: Mis meetmed võetakse, et tagada Palonosetron Hospira ohutu ja efektiivne kasutamine?
English: A risk management plan has been developed to ensure that Palonosetron Hospira is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Palonosetron Hospira võimalikult ohutu kasutamine.
English: When 5HT attaches to these receptors, it normally causes nausea and vomiting.
Estonian: 5HT seondumine nende retseptoritega põhjustab iiveldust ja oksendamist.
English: The Committee recommended that Palonosetron Hospira be approved for use in the EU.
Estonian: Komitee soovitas Palonosetron Hospira kasutamise Euroopa Liidus heaks kiita.
English: It is used in adults and children 1 month of age or older for chemotherapy with medicines that are either a strong trigger of nausea and vomiting (such as cisplatin) or a moderate trigger (such as cyclophosphamide, doxorubicin or carboplatin).
Estonian: Seda kasutatakse täiskasvanutel ja vähemalt 1 kuu vanustel lastel kas tugevat iiveldust ja oksendamist põhjustavate keemiaravi ainete (nt tsisplatiin) või mõõdukat iiveldust ja oksendamist põhjustavate keemiaravi ainete (nt tsüklofosfamiid, doksorubitsiin või karboplatiin) korral.
English: By blocking these receptors, Palonosetron Hospira prevents the nausea and vomiting that often happen after chemotherapy.
Estonian: Nende retseptorite blokeerimise abil ennetab Palonosetron Hospira iiveldust ja oksendamist, mis sageli esinevad pärast keemiaravi.
English: The company provided data from the published literature on palonosetron.
Estonian: Ettevõte esitas palonosetrooni kohta avaldatud kirjandusest pärinevad andmed.
English: No additional studies were needed as Palonosetron Hospira is a generic medicine that is given by injection and contains the same active substance as the reference medicine, Aloxi.
Estonian: Lisauuringuid ei olnud vaja, sest Palonosetron Hospira on süstitav geneeriline ravim, mis sisaldab sama toimeainet kui võrdlusravim Aloxi.
English: What is Palonosetron Hospira and what is it used for?
Estonian: Mis on Palonosetron Hospira ja milleks seda kasutatakse?
English: This means that it stops a chemical in the body called 5-hydroxytryptamine (5HT, also known as serotonin) from attaching to 5HT3 receptors in the gut.
Estonian: See takistab organismi teatud keemilise aine 5-hüdroksütrüptamiini (5HT ehk serotoniini) seondumist soolestiku 5HT3-retseptoritega.
English: Because Palonosetron Hospira is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Palonosetron Hospira on geneeriline ravim, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Palonosetron Hospira has been shown to be comparable to Aloxi.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Palonosetron Hospira sarnane toime ravimiga Aloxi.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Palonosetron Hospira, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Palonosetron Hospira omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: This means that Palonosetron Hospira is similar to a ‘reference medicine' already authorised in the European Union (EU) called Aloxi.
Estonian: See tähendab, et Palonosetron Hospira on sarnane võrdlusravimiga Aloxi, millel juba on Euroopa Liidus müügiluba.
English: Palonosetron Hospira palonosetron
Estonian: Palonosetron Hospira palonosetroon
English: It is not intended to provide practical advice on how to use Palonosetron Hospira.
Estonian: Hindamisaruandes ei anta Palonosetron Hospira kasutamise praktilisi nõuandeid.
English: It may be given with a corticosteroid (another type of medicine that can be used to prevent nausea and vomiting) to increase the effect.
Estonian: Mõju suurendamiseks võib ravimit anda koos kortikosteroidiga (teist liiki ravim, mida kasutatakse iivelduse ja oksendamise ennetamiseks).
English: This is a summary of the European public assessment report (EPAR) for Palonosetron Hospira.
Estonian: See on ravimi Palonosetron Hospira Euroopa avaliku hindamisaruande kokkuvõte.
English: For practical information about using Palonosetron Hospira, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Palonosetron Hospira kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Palonosetron Hospira is used to prevent nausea (feeling sick) and vomiting caused by chemotherapy (medicines to treat cancer).
Estonian: Palonosetron Hospirat kasutatakse, et ennetada iiveldust ja oksendamist, mida põhjustab keemiaravi (vähiravimid).
English: The active substance in Palonosetron Hospira, palonosetron, is a ‘5HT3 antagonist'.
Estonian: Palonosetron Hospira toimeaine palonosetroon on 5HT3 antagonist.
English: Therefore, the CHMP's view was that, as for Aloxi, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Aloxi korral, ületab Palonosetron Hospira kasulikkus sellega kaasnevad riskid.
English: Palonosetron Hospira is a ‘generic medicine'.
Estonian: Palonosetron Hospira on geneeriline ravim.
English: For more information about treatment with Palonosetron Hospira, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Palonosetron Hospiraga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: the solution should be given by infusion (drip) into a vein over 15 minutes at a dose of 20 micrograms per kilogram body weight.
Estonian: Lastele manustatakse lahust 15-minutilise veeniinfusioonina annuses 20 µg kehamassi kg kohta.
English: Why is Palonosetron Hospira approved?
Estonian: Miks Palonosetron Hospira heaks kiideti?
English: Palonosetron Hospira should only be given before chemotherapy and can only be obtained with a prescription.
Estonian: Palonosetron Hospirat tohib kasutada üksnes enne keemiaravi.
English: Other information about Palonosetron Hospira
Estonian: Muu teave Palonosetron Hospira kohta
English: How has Palonosetron Hospira been studied?
Estonian: Kuidas Palonosetron Hospirat uuriti?
English: Palonosetron Hospira contains the active substance palonosetron.
Estonian: Palonosetron Hospira sisaldab toimeainena palonosetrooni.
English: How is Palonosetron Hospira used?
Estonian: Kuidas Palonosetron Hospirat kasutatakse?
English: What are the benefits and risks of Palonosetron Hospira?
Estonian: Milles seisneb Palonosetron Hospira kasulikkus ja mis riskid ravimiga kaasnevad?
English: Date of first authorisation: 10 January 2008 Date of latest renewal: 20 September 2012
Estonian: Müügiloa esmase väljastamise kuupäev: 10. jaanuar 2008 Müügiloa viimase uuendamise kuupäev: 20. september 2012
English: Other medicines and TESAVEL
Estonian: Muud ravimid ja TESAVEL
English: - an allergic reaction to TESAVEL (see section 4).
Estonian: - allergiline reaktsioon TESAVELile (vt lõik 4).
English: STOP taking TESAVEL and contact a doctor immediately if you notice any of the following serious side effects:
Estonian: LÕPETAGE TESAVELi võtmine ja võtke otsekohe ühendust arstiga, kui märkate mõnda järgmistest tõsistest kõrvaltoimetest:
English: What TESAVEL contains
Estonian: Mida TESAVEL sisaldab
English: What you need to know before you take TESAVEL
Estonian: Mida on vaja teada enne TESAVELi võtmist
English: If you stop taking TESAVEL
Estonian: Kui te lõpetate TESAVELi võtmise
English: The level of digoxin in your blood may need to be checked if taking with TESAVEL.
Estonian: Vajalik võib olla digoksiini taseme kontrollimine teie veres, kui seda võetakse koos TESAVELiga.
English: Do not take TESAVEL - if you are allergic to sitagliptin or any of the other ingredients of this medicine (listed in section 6).
Estonian: Ärge võtke TESAVELi - kui olete sitagliptiini või selle ravimi mis tahes koostisosade (loetletud lõigus 6) suhtes allergiline.
English: If you forget to take TESAVEL
Estonian: Kui te unustate TESAVELi võtta
English: If you take more TESAVEL than you should If you take more than the prescribed dosage of this medicine, contact your doctor immediately.
Estonian: Kui te võtate TESAVELi rohkem kui ette nähtud Kui te võtate seda ravimit määratust suuremas annuses, pöörduge otsekohe oma arsti poole.
English: Your doctor may ask you to stop TESAVEL.
Estonian: Võimalik, et arst soovitab teil lõpetada TESAVELi võtmise.
English: What TESAVEL is and what it is used for What you need to know before you take TESAVEL How to take TESAVEL
Estonian: Mis ravim on TESAVEL ja milleks seda kasutatakse Mida on vaja teada enne TESAVELi võtmist Kuidas TESAVELi võtta
English: Due to lack of human data, TESAVEL should not be used during pregnancy.
Estonian: Inimestelt saadud andmete puudumise tõttu ei tohi TESAVELi raseduse ajal kasutada.
English: What TESAVEL is and what it is used for
Estonian: Mis ravim on TESAVEL ja milleks seda kasutatakse
English: You should not use this medicine during pregnancy.
Estonian: Seda ravimit ei tohi raseduse ajal kasutada.
English: Do not use this medicine after the expiry date which is stated on the blister and the carton after 'EXP'.
Estonian: Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud blisterpakendil ja karbil pärast märget „EXP“.
English: In addition, patients should be alerted to the risk of hypoglycaemia when TESAVEL is used in combination with a sulphonylurea or with insulin.
Estonian: Lisaks peavad patsiendid olema hoiatatud riskist hüpoglükeemia tekkeks, kui TESAVELi kasutatakse kombinatsioonis sulfonüüluurea või insuliiniga.
English: If a dose of TESAVEL is missed, it should be taken as soon as the patient remembers.
Estonian: Kui TESAVELi annus ununeb manustamata, tuleb see manustada niipea, kui patsiendile meenub.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with TESAVEL in one or more subsets of the paediatric population in type 2 diabetes mellitus (see section 4.2 for information on paediatric use).
Estonian: Euroopa Ravimiamet on peatanud kohustuse esitada TESAVELiga läbi viidud uuringute tulemused laste ühe või mõne alarühma kohta II tüüpi diabeedi korral (teave lastel kasutamise kohta: vt lõik 4.2).
English: Method of administration TESAVEL can be taken with or without food.
Estonian: Manustamisviis TESAVELi võib manustada koos toiduga või ilma.
English: What TESAVEL looks like and contents of the pack
Estonian: Kuidas TESAVEL välja näeb ja pakendi sisu
English: Because there is a dosage adjustment based upon renal function, assessment of renal function is recommended prior to initiation of TESAVEL and periodically thereafter.
Estonian: Kuna annuse muutmine sõltub neerufunktsioonist, on soovitatav enne TESAVELi manustamist hinnata neerufunktsiooni ja jälgida seda pärast ravimi võtmist perioodiliselt.
English: TESAVEL should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
Estonian: Üldine TESAVELi ei tohi kasutada I tüüpi diabeediga patsientidel või diabeetilise ketoatsidoosi raviks.
English: If pancreatitis is suspected, TESAVEL and other potentially suspect medicinal products should be discontinued; if acute pancreatitis is confirmed, TESAVEL should not be restarted.
Estonian: Pankreatiidi kahtluse korral tuleb lõpetada TESAVELi ja teiste seda potentsiaalselt põhjustada võivate ravimpreparaatide kasutamine; ägeda pankreatiidi kinnitatud diagnoosi korral ei tohi TESAVELi kasutamist jätkata.
English: If a hypersensitivity reaction is suspected, TESAVEL should be discontinued.
Estonian: Kui kahtlustatakse ülitundlikkusreaktsiooni, tuleb TESAVELravi katkestada.
English: 5 How to store TESAVEL Contents of the pack and other information
Estonian: Kuidas TESAVELi säilitada Pakendi sisu ja muu teave
English: Since co-administration of a high-fat meal with sitagliptin had no effect on the pharmacokinetics, TESAVEL may be administered with or without food.
Estonian: Kuna sitagliptiini manustamisel koos suure rasvasisaldusega einega ei muutunud ravimi farmakokineetika, võib TESAVELi manustada koos toiduga või ilma.
English: For adult patients with type 2 diabetes mellitus, TESAVEL is indicated to improve glycaemic control:
Estonian: II tüüpi diabeediga täiskasvanud patsientidel on TESAVEL näidustatud parema glükeemilise kontrolli saavutamiseks:
English: TESAVEL has no or negligible influence on the ability to drive and use machines.
Estonian: TESAVEL ei mõjuta või mõjutab ebaoluliselt autojuhtimise ja masinate käsitsemise võimet.
English: TESAVEL contains the active substance sitagliptin which is a member of a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) that lowers blood sugar levels in adult patients with type 2 diabetes mellitus.
Estonian: TESAVEL sisaldab toimeainet sitagliptiin, mis kuulub ravimite rühma, mida nimetatakse DPP-4 (dipeptidüülpeptidaas-4) inhibiitoriteks ja mis alandavad II tüüpi suhkurtõvega täiskasvanud patsientide veresuhkru taset.
English: For patients with severe renal impairment (GFR ≥ 15 to <30 mL/min) or with end-stage renal disease (ESRD) (GFR < 15 mL/min), including those requiring haemodialysis or peritoneal dialysis, the dose of TESAVEL is 25 mg once daily.
Estonian: Raske neerukahjustusega patsientidel (GFR ≥ 15 kuni < 30 ml/min) või lõppstaadiumis neeruhaigusega patsientidel (GFR < 15 ml/min), sh need, kes vajavad hemodialüüsi või peritoneaaldialüüsi, on TESAVELi annus 25 mg üks kord ööpäevas.